Pharvaris (NASDAQ: PHVS) CTO reports option grants and share holdings

Rhea-AI Filing Summary

Pharvaris N.V. executive Stefan Andreas Abele, Chief Technical Ops Officer, reports his initial equity holdings. He holds several stock option awards over common shares, including options exercisable at $28.0000, $16.0500, $22.3100 and $16.4000, with expiration dates between November 15, 2033 and March 3, 2036. These options cover 60,000, 60,000, 40,000 and 89,500 underlying common shares, respectively. He also reports direct ownership of 43,942 shares of common stock as of March 18, 2026, which includes restricted stock units granted under the company’s equity plan that vest over time according to the schedules described in the footnotes.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Abele Stefan Andreas

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Ops Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	43,942(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	03/03/2036	Common Stock	60,000	$28	D
Stock Option (Right to Buy)	(3)	04/12/2035	Common Stock	60,000	$16.05	D
Stock Option (Right to Buy)	(4)	04/11/2034	Common Stock	40,000	$22.31	D
Stock Option (Right to Buy)	(5)	11/15/2033	Common Stock	89,500	$16.4	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% vested March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -6,849 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.

2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.

3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on November 15, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Stefan Abele	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Pharvaris (PHVS) Form 3 for Stefan Andreas Abele report?

The Form 3 reports initial equity holdings for Chief Technical Ops Officer Stefan Andreas Abele, including stock options over multiple blocks of Pharvaris common shares and direct ownership of 43,942 common shares as of March 18, 2026, with detailed vesting terms in the footnotes.

How many Pharvaris (PHVS) common shares are covered by Abele’s stock options?

Abele’s options cover several blocks of common shares, including 60,000 shares at an exercise price of $28.0000, 60,000 shares at $16.0500, 40,000 shares at $22.3100 and 89,500 shares at $16.4000, all expiring between November 15, 2033 and March 3, 2036.

What direct common stock holdings does Stefan Andreas Abele report in Pharvaris (PHVS)?

Abele reports direct ownership of 43,942 common shares of Pharvaris N.V. as of March 18, 2026. According to the footnotes, this figure includes restricted stock units granted under the company’s equity plan that settle in common stock and vest over time.

How do Stefan Andreas Abele’s Pharvaris (PHVS) stock options vest?

The options generally vest 25% on a key date, then monthly. Each grant specifies that 25% of the option vests on its initial vesting date, such as March 3, 2027 or March 12, 2026, with the remaining shares vesting in 1/48 monthly installments thereafter.

What are the key details of Abele’s restricted stock units in Pharvaris (PHVS)?

The footnotes describe several RSU grants and vesting schedules, including awards granted on March 3, 2026, March 12, 2025 and April 11, 2024. Each award vests 25% on the first anniversary grant date, with the remaining RSUs vesting monthly thereafter and settling in common stock.